VVOS
Vivos·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VVOS
Vivos Therapeutics, Inc.
A medical technology company focused on treatment methods for breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea and snoring in adults
7921 Southpark Plaza, Suite 210, Littleton, CO 80120
--
Vivos Therapeutics, Inc., was re-registered as a domestic Delaware corporation on August 12, 2020. The Company is a revenue stage medical technology company focused on developing and commercializing a suite of innovative diagnostic and multidisciplinary treatment models for patients with dental-facial abnormalities and a wide range of medical conditions that may result from them, including mild to severe obstructive sleep apnea (known as OSA) and adult snoring.
Earnings Call
Q4/2024
Estimate EPS-0.43
Actual EPS0.41
Estimate Revenue3.89M
Actual Revenue3.70M
Vivos Therapeutics Q4 2024: Contradictions in Marketing Strategy, Expansion Plans, and Cost Management
Apr 01,2025 12:25
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS-0.4
Actual EPS-0.45
Estimate Revenue3.67M
Actual Revenue3.02M
Vivos Therapeutics' Q1 2025: Key Contradictions in Rebis Alliance Performance and Revenue Growth Expectations
May 20,2025 10:53
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VVOS has released its 2025 Q3 earnings. EPS was reported at -0.49, versus the expected -0.51, beating expectations. The chart below visualizes how VVOS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VVOS has released its 2025 Q3 earnings report, with revenue of 6.78M, reflecting a YoY change of 75.73%, and net profit of -5.40M, showing a YoY change of -106.42%. The Sankey diagram below clearly presents VVOS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
